GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
gipss score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–0
  • Intermediate-1 Risk1–1
  • Intermediate-2 Risk2–2
  • High Risk3–6
Direct Clinical Answer

The GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include karyotype risk. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

The GIPSS is a genetically-based prognostic scoring system for primary myelofibrosis that relies exclusively on cytogenetic and molecular genetic markers. This system eliminates subjective clinical variables and provides more accurate risk stratification for treatment planning, particularly for allogeneic stem cell transplant decisions.

Clinical Indication

The GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis is indicated for bedside clinical practice to support The GIPSS is a genetically-based prognostic scoring system for primary myelofibrosis that relies exclusively on cytogenetic and molecular genetic markers. This system eliminates subjective clinical variables and provides more accurate risk stratification for treatment planning, particularly for allogeneic stem cell transplant decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

GIPSS Score = Karyotype Risk Points + CALR Type 1 Absence Points + ASXL1 Mutation Points + SRSF2 Mutation Points + U2AF1Q157 Mutation Points, where total score ranges from 0-6 points

Input Parameters

NameTypeRequiredDescription
karyotype_riskstringYesCytogenetic risk classification based on karyotype analysis
calr_type1_mutationstringYesPresence of type 1/like CALR (calreticulin) mutation
asxl1_mutationstringYesPresence of ASXL1 (Additional Sex Combs-Like 1) mutation
srsf2_mutationstringYesPresence of SRSF2 (Serine/Arginine-Rich Splicing Factor 2) mutation
u2af1q157_mutationstringYesPresence of U2AF1Q157 (U2 Small Nuclear RNA Auxiliary Factor 1) mutation

Score Interpretation & Guidance

RangeStageDescription
0–0Low RiskExcellent prognosis
1–1Intermediate-1 RiskGood prognosis
2–2Intermediate-2 RiskIntermediate prognosis
3–6High RiskPoor prognosis

Evidence-Based References (EBM)

  • Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z.DOI: 10.1038/s41375-018-0107-z
  • Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726-2731. doi: 10.1038/leu.2017.169.DOI: 10.1038/leu.2017.169
  • Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310-318. doi: 10.1200/JCO.2017.76.4886.DOI: 10.1200/JCO.2017.76.4886

Related calculators